Literature DB >> 16444436

Evaluation of a rapid automated assay for analysis of von Willebrand ristocetin cofactor activity.

Karin Strandberg1, Stefan Lethagen, Kerstin Andersson, Margareta Carlson, Andreas Hillarp.   

Abstract

A commercially available turbidometric assay has been evaluated for the measurement of von Willebrand factor ristocetin cofactor activity (VWF:RCo). The assay is simple, rapid, and can be cost-effectively performed on automated coagulation analyzers. This study's aim is to illustrate the performance of the automated VWF:RCo assay and its capacity to identify patients with von Willebrand disease (VWD). By direct comparison with a conventional VWF:RCo assay, performed on an aggregometer, the concordance between the two assays was 96%. With minor modifications, the automated assay showed a detection level of 0.03 kIU/L with linearity to 2.00 kIU/L. The imprecision of the automated assay was reduced compared to the conventional assay procedure with CV of 6.8% at the 1.00 kIU/L level and 8.6% at the 0.30 kIU/L level. The automated VWF:RCo assay was also suitable as a screening test to detect VWD in patients investigated for the cause of an increased bleeding tendency. In this situation the automated VWF:RCo assay was tested simultaneously with an automated immunoassay for von Willebrand antigen. Receiver operating curves for the diagnosis of VWD showed a greater area under the curve for the automated VWF:RCo assay compared to the immunoassay, 0.98 vs. 0.94, although the difference did not reach significance. In conclusion, the modified automated VWF:RCo assay shows better precision, lower detection limit, is faster to perform with a lower cost per test compared to the conventional aggregometer based VWF:RCo activity method and is an alternative to an antigen immunoassay as a screening test for VWD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16444436     DOI: 10.1177/107602960601200110

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  4 in total

1.  Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura.

Authors:  Marie Scully; Paul Knöbl; Karim Kentouche; Lawrence Rice; Jerzy Windyga; Reinhard Schneppenheim; Johanna A Kremer Hovinga; Michiko Kajiwara; Yoshihiro Fujimura; Caterina Maggiore; Jennifer Doralt; Christopher Hibbard; Leah Martell; Bruce Ewenstein
Journal:  Blood       Date:  2017-09-14       Impact factor: 22.113

2.  Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.

Authors:  Joan C Gill; Giancarlo Castaman; Jerzy Windyga; Peter Kouides; Margaret Ragni; Frank W G Leebeek; Ortrun Obermann-Slupetzky; Miranda Chapman; Sandor Fritsch; Borislava G Pavlova; Isabella Presch; Bruce Ewenstein
Journal:  Blood       Date:  2015-08-03       Impact factor: 22.113

3.  A Comparative Evaluation of an Automated Functional Assay for Von Willebrand Factor Activity in Type 1 Von Willebrand Disease.

Authors:  Shiue-Wei Lai; Chia-Yau Chang; Shin-Nan Cheng; Shu-Hsia Hu; Chung-Yu Lai; Yeu-Chin Chen
Journal:  Int J Gen Med       Date:  2021-09-02

4.  Patients Referred for Bleeding Symptoms of Unknown Cause: Does Evaluation of Thrombin Generation Contribute to Diagnosis?

Authors:  Elena Holm; Eva Zetterberg; Susanna Lövdahl; Erik Berntorp
Journal:  Mediterr J Hematol Infect Dis       Date:  2016-02-10       Impact factor: 2.576

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.